骨质疏松症的临床研究进展  

Clinical Research Progress of Osteoporosis

作　　者：余晓波[1] YU Xiaobo(The Third People’s Hospital of Hechi,Guangxi,Hechi 547000,China)

机构地区：[1]广西河池市第三人民医院,广西河池547000

出　　处：《中国医学创新》2022年第21期175-178,共4页Medical Innovation of China

摘　　要：我国目前人均寿命延长,老龄化趋势日益严重,故骨质疏松症成为了影响人类健康的重要问题。由于骨质疏松症的病因比较复杂,年龄增长、性激素分泌减少等原因,临床中并没有直接测量和评估骨强度的方法,而骨密度是临床诊断骨质疏松症的常用指标。骨质疏松增加了病残率与死亡率,严重危害患者的家庭,同时也给社会带来了沉重的负担,为此,早预防、早诊断、早治疗十分必要。基于此,本文总结相关文献内容,并介绍骨质疏松的常见病因、诊断标准和治疗药物、非药物治疗的研究进展,为今后研究提供参考。In my country,the average life expectancy is prolonged and the aging trend is becoming more and more serious.Therefore,osteoporosis has become an important problem affecting human health.Due to the complicated etiology of osteoporosis,aging,decreased sex hormone secretion and other reasons,there is no clinical method to directly measure and evaluate bone strength,and bone density is a common index for clinical diagnosis of osteoporosis.Osteoporosis increases the disability rate and mortality rate,seriously endangers the family of patients,and also brings a heavy burden to the society.For this reason,early prevention,early diagnosis and early treatment are necessary.Based on this,this article summarizes the content of the relevant literature,and introduces the common causes of osteoporosis,diagnostic criteria and the progress of the research on therapeutic drugs and non-drug treatments,so as to provide references for future research.

关 键 词：骨质疏松症 诊断标准 骨吸收抑制剂 骨形成促进剂 

分 类 号：R580[医药卫生—内分泌]